我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

依折麦布在分子水平治疗冠心病并发糖尿病的进展

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2016年第6期
页码:
736-740
栏目:
综述
出版日期:
2016-07-05

文章信息/Info

Title:
Progress of ezetimibe in molecular-level treatment of coronary heart disease complicated with diabetes
作者:
丁玲玲; 吴晓羽
（哈尔滨医科大学第一附属医院心血管内科，黑龙江 哈尔滨 150001）
Author(s):
DING ling-ling;  WU xiao-yu
(Department of Cardiology, First Affiliated Hospital, Harbin Medical University, Harbin 150001, Heilongjiang, China)
关键词:
依折麦布; 尼曼-皮克C1型类似蛋白1; 胰高血糖素样肽-1; 二肽基肽酶-4
Keywords:
ezetimibe;  Niemann-Pick C1 Like 1;  glucagon-like peptide 1;  dipeptidyl peptidase 4
分类号:
R543.5
DOI:
-
文献标识码:
A
摘要:
尼曼-皮克C1型类似蛋白(NPC1L)1在依折麦布降脂治疗中起到举足轻重的作用。同时依折麦布可以降低血清二肽基肽酶(DPP)-4活性和增加血清活性胰高血糖素样肽(GLP)-1水平，在糖尿病患者中对血糖可以进行一定程度的控制。临床研究表明，依折麦布具有降脂，预防冠心病，降低心血管发病率，尤其是应用在冠心病并发糖尿病患者中。近年来人们对NPC1L1、DPP-4和GLP-1在冠心病并发糖尿病患者中的作用有了更深一步的研究。
Abstract:
Niemann-Pick C1 Like 1 (NPC1L1) plays a decisive role in ezetimibe in lipid-lowering therapy. Ezetimibe can reduce serum dipeptidyl peptidase 4 (DPP-4) activity and increase the activity of serum glucagon-like peptide 1 (GLP-1), thus controlling blood glucose to a certain degree in diabetic patients. Clinical studies have shown that ezetimibe can lower lipid levels, prevent coronary heart disease (CHD) and reduce the incidence of cardiovascular diseases, especially in patients with CHD complicated with diabetes. In recent years, more in-depth research has been conducted concerning the roles of NPC1L1, GLP-1 and DPP-4 in patients with CHD complicated with diabetes.

参考文献/References

[1]方沐潮,曹 乐,贝伟剑.胆固醇吸收靶点NPC1L1研究进展[J].药物资讯,2013,2:19-26.
[2]Robinson JG,Smith B,Maheshwari N,et al.Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis[J].JAm Coll Cardiol,2005,46(10):1855-1862.
[3]张艳平,许崇利,刘 霞,等.胆固醇转运蛋白NPC1L1的研究进展[J].中国动物检疫,2012,29(6):76-79.
[4]Mannucci E,Pala L,Ciani S,et al.Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus[J].Diabetologia,2005,48(6):1168-1172.
[5]Ryskjaer J,Deacon CF,Carr RD,et al.Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels,but is not acutely affected by food intake[J].Eur J Endocrinol,2006,155(3):485-493.
[6]Yang SJ,Choi JM,Kim L,et al.Chronic administration of ezetimibe increases active glucagon-like peptide-1 and improves glycemic control and pancreatic beta cell mass in a rat model of type 2 diabetes[J].Biochem Biophys Res Commun,2011,407(1):153-157.
[7]Chang E,Kim L,Choi JM,et al.Ezetimibe stimulates intestinal glucagon-like peptide 1 secretion via the MEK/ERK pathway rather than dipeptidyl peptidase 4 inhibition[J].Metab Clin Exp,2015,64(5):633-641.
[8]Ravassa S,Beaumont J,Huerta A,et al.Association of low GLP-1 with oxidative stress is related to cardiac disease and outcome in patients with type 2 diabetes mellitus: a pilot study[J].Free Radic Biol Med,2015,81:1-12.
[9]Velez M,Peterson EL,Wells K,et al.Association of antidiabetic medications targeting the glucagon-like peptide 1 pathway and heart failure events in patients with diabetes[J].J Card Fail, 2015,21(1):2-8.
[10]Bu?dak ?,?abuzek K,Bu?dak RJ,et al.Exenatide(a GLP-1 agonist)improves the antioxidative potential of in vitro cultured human monocytes/macrophages[J].Naunyn Schmiedebergs Arch Pharmacol,2015,388(9):905-919.
[11]McCormick LM,Hoole SP,White PA,et al.Pre-treatment with glucagon-like Peptide-1 protects against ischemic left ventricular dysfunction and stunning without a detected difference in myocardial substrate utilization[J].JACC Cardiovasc Interv,2015,8(2):292-301.
[12]Noyan-Ashraf MH,Shikatani EA,Schuiki I,et al.A glucagon-like peptide-1 analog reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity[J].Circulation,2013,127(1):74-85.
[13]Chang G,Zhang P,Ye L,et al.Protective effects of sitagliptin on myocardial injury and cardiac function in an ischemia/reperfusion rat model[J].Eur J Pharmacol,2013,718(1-3):105-113.
[14]Leibovitz E,Gottlieb S,Goldenberg I,et al.Sitagliptin pretreatment in diabetes patients presenting with acute coronary syndrome: results from the Acute Coronary Syndrome Israeli Survey(ACSIS)[J].Cardiovasc Diabetol,2013,12:53.
[15]Clarke SJ,McCormick LM,Dutka DP.Optimising cardioprotection during myocardial ischaemia:targeting potential intracellular pathways with glucagon-like peptide-1[J].Cardiovasc Diabetol,2014,13:12.
[16]Scheen AJ.Cardiovascular effects of dipeptidyl peptidase-4 inhibitors:from risk factors to clinical outcomes[J].Postgrad Med,2013,125(3):7-20.
[17]Chinda K,Sanit J,Chattipakorn S,et al.Dipeptidyl peptidase-4 inhibitor reduces infarct size and preserves cardiac function via mitochondrial protection in ischaemia-reperfusion rat heart[J].Diab Vasc Dis Res,2014,11(2):75-83.
[18]吕 荣,李道鸿,张国栋,等.依折麦布联合辛伐他汀对冠心病及糖尿病患者的血LDL-C达标和安全性观察[J].中国循证心血管医学杂志,2012,4(2):152-154.
[19]龙飞飞,王 杨,姜明珠,等.依折麦布辛伐他汀片短期内降脂疗效[J].中国老年学杂志,2014,34(18):5278-5279.
[20]Gouni-Berthold I,Berthold HK,Gylling H,et al.Effects of ezetimibe and/or simvastatin on LDL receptor protein expression and on LDL receptor and HMG-CoA reductase gene expression: a randomized trial in healthy men[J].Atherosclerosis,2008,198(1):198-207.
[21]Farnier M.Ezetimibe/statin combination therapy to treat patients with type 2 diabetes[J].Atheroscler Suppl,2015,17:2-8.
[22]Lally S,Tan CY,Owens D,et al.Messenger RNA levels of genes involved in dysregulation of postprandial lipoproteins in type 2 diabetes:the role of Niemann-Pick C1-like 1,ATP-binding cassette,transporters G5 and G8,and of microsomal triglyceride transfer protein[J].Diabetologia,2006,49(5):1008-1016.
[23]Shigematsu E,Yamakawa T,Taguri M,et al.Efficacy of ezetimibe is associated with gender and baseline lipid levels in patients with type 2 diabetes[J].J Atheroscler Thromb,2012,19(9):846-853.
[24]Tomkin GH.Targets for intervention in dyslipidemia in diabetes[J].Diabetes Care,2008,31(Suppl 2):S241-S248.
[25]Malhotra P,Boddy CS,Soni V,et al.D-Glucose modulates intestinal Niemann-Pick C1-like 1(NPC1L1)gene expression via transcriptional regulation[J].Am J Physiol Gastrointest Liver Physiol,2013,304(2):G203-G210.
[26]Okada K,Yagyu H,Kotani K,et al.Lipid-lowering effects of ezetimibe for hypercholesterolemic patients with and without type 2 diabetes mellitus[J].Endocr J,2010,57(10):903-908.
[27]Hiramitsu S,Miyagishima K,Ishii J,et al.Effect of ezetimibe on lipid and glucose metabolism after a fat and glucose load[J].J Cardiol,2012 60(5):395-400.
[28]Tsunoda T,Nozue T,Yamada M,et al.Effects of ezetimibe on atherogenic lipoproteins and glucose metabolism in patients with diabetes and glucose intolerance[J].Diabetes Res Clin Pract,2013,100(1):46-52.
[29]Lindholm MW,Elmén J,Fisker N,et al.PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates[J].Mol Ther,2012,20(2):376-381.
[30]Tibolla G,Norata GD,Artali R,et al.Proprotein convertase subtilisin/kexin type 9(PCSK9):from structure-function relation to therapeutic inhibition[J].Nutr Metab Cardiovasc Dis,2011,21(11):835-843.

备注/Memo

备注/Memo:
收稿日期：2015-10-27.
基金项目：黑龙江省自然基金项目资助（D201058）；哈尔滨市科技局项目资助（2012RFXXS056）
通讯作者：吴晓羽，主任医师，主要从事冠心病和心律失常研究Email：xiaoyu-wu2006@163.com
作者简介：丁玲玲，硕士生Email：930387322@qq.com
更新日期/Last Update: 2016-07-10